ABH’s wholly owned subsidiary, Angel Biomedical Ltd (ABL) will take ownership of the manufacturing plant.
The 6,500ft² facility comprises one large Grade C clean room, two smaller grade B rooms, and laboratory and office suite, for the production of purified GMP medical grade collagen.
ABH executive chairman Paul Harper said the formation of ABL provides significant strategic advantages to the Group, and the distinctive competencies offered will provide a one-stop shop for companies in the regenerative medicine space.
"ABL will also provide access to a range of new markets by offering customers the means by which to convert advanced biologics and cell therapies currently being manufactured by Angel into formulated, finished products such as medical devices and in vitro diagnostics," Harper added.